Advertisement

Search Results

Advertisement



Your search for Caroline Helwick matches 18 pages

Showing 1 - 18


breast cancer

SABCS 2014: BOLERO-3: Everolimus Plus Trastuzumab/Paclitaxel Misses the Mark in First-Line HER2 Advanced Breast Cancer

The addition of everolimus to weekly trastuzumab (Herceptin) plus paclitaxel did not improve outcomes in the phase III BOLERO-1/TRIO-019, but did provide a “signal” in the hormone receptor–negative subset. The study was reported at the 2014 San Antonio Breast Cancer Symposium by...

breast cancer

SABCS 2014: Adding Carboplatin to Neoadjuvant Therapy Increases Pathologic Complete Response Rates Across Subtypes in Triple-Negative Breast Cancer

Among women with triple-negative breast cancer, both basal-like and non–basal-like tumors were equally likely to demonstrate a pathologic complete response to neoadjuvant chemotherapy, but they responded differently to exposure to carboplatin and bevacizumab (Avastin), in an analysis of the...

breast cancer

SABCS 2014: Pembrolizumab Holds Promise in Breast Cancer, Early Studies Suggest

Single-agent treatment with the immunotherapy drug pembrolizumab (Keytruda) produced a “signal of activity” and led to some durable response, in patients with metastatic triple-negative breast cancer, Rita Nanda, MD, of the University of Chicago, reported at the 2014 San Antonio Breast...

breast cancer

ESMO 2014: CLEOPATRA Study Shows ‘Unprecedented’ Survival With Dual HER2 Blockade in Metastatic Breast Cancer

In the final overall survival analysis of the phase III CLEOPATRA trial, patients with HER2-positive metastatic breast cancer patients lived 15.7 months longer if they received pertuzumab (Perjeta) in addition to trastuzumab (Herceptin) and docetaxel, investigators reported at the ESMO 2014...

breast cancer

Surgery for Metastatic Breast Cancer Associated With High Complication Rate

Surgery for metastatic breast cancer conveys a significantly increased risk for morbidity and mortality at 30 days vs surgery for earlier-stage disease, according to researchers from the University of Toronto who presented their findings at the American Society of Breast Surgeons Annual Meeting in...

breast cancer

Axillary Radiotherapy Associated With Fewer Side Effects Than Lymph Node Dissection in AMAROS Analysis

Radiation therapy, an emerging treatment modality for breast cancer in the lymph nodes, is associated with significantly fewer postoperative complications than axillary lymph node dissection, according to a detailed analysis of morbidity from the AMAROS trial presented at a press briefing prior to...

breast cancer

Cryoablation of Breast Tumors Successful in 69% of Patients With Early-Stage Disease in Phase II Trial

Cryoablation of breast tumors, which destroys lesions by exposing them to extremely low temperatures, may be a promising alternative to surgery in carefully selected women with early-stage disease, according to a study presented at the American Society of Breast Surgeons Annual Meeting in Las...

breast cancer

Adjuvant Paclitaxel/Trastuzumab Tolerable, Benefits Women With Stage I HER2-Positive, Node-Negative Breast Cancer

There may be a benefit for treating small HER2-positive tumors and this can be done with little toxicity, according to a multicenter study presented at the 2013 San Antonio Breast Cancer Symposium (Abstract S1-04). Previous studies of chemotherapy plus anti-HER2 treatment for node-negative...

breast cancer

PIK3CA Mutations Predictive of Resistance to Neoadjuvant Therapy in HER2/HR-Positive Breast Cancers

Women with HER2-positive, hormone receptor-positive breast cancer with mutations in the PI3K/AKT pathway may respond poorly to neoadjuvant therapy, German researchers reported at the 2013 San Antonio Breast Cancer Symposium (Abstract S4-06). “We found that very few women with HER2-positive...

breast cancer

NeoALTTO Trial Links Pathologic Complete Response to Clinical Outcomes

Final results of the phase III NeoALTTO trial have confirmed the value of pathologic complete response to dual HER2 blockade in the neoadjuvant setting. The achievement of pathologic complete response was associated with significantly improved event-free survival and overall survival in some women...

breast cancer
gynecologic cancers

Robust Activity Shown for Investigational PARP Inhibitor BMN673 in BRCA-Related Cancers

In patients with heavily pretreated advanced BRCA-related breast and ovarian cancers, the investigational poly (ADP-ribose) polymerase (PARP) inhibitor BMN673 produced an objective response rate of more than 40% and delayed disease progression by more than 6 months, according to a multicenter phase ...

breast cancer

Program Chairs Highlight Abstracts of Interest for the 2013 CTRC-AACR San Antonio Breast Cancer Symposium

The Program Chairs of the 2013 CTRC-AACR San Antonio Breast Cancer Symposium, which will be held December 10–14, 2013, have highlighted what they consider to be the most important abstracts to be presented at the Symposium. In a telebriefing in advance of the December meeting, C. Kent...

breast cancer
issues in oncology

ECC 2013: PI3KCA-Mutant Tumors Not Likely to Respond to Neoadjuvant HER2 Blockade

In patients with early breast cancer receiving anti-HER2 therapy in the NeoALTTO trial, mutations in PIK3CA were associated with lower rates of pathologic complete response, Jose Baselga, MD, reported at the European Cancer Congress 2013 (Abstract 1859) in Amsterdam. In patients treated with the...

breast cancer
gynecologic cancers
issues in oncology

ECC 2013: Continuous Combined Hormone Replacement Therapy Protects Against Endometrial Cancer

According to an analysis of the Women’s Health Initiative, continuous combined use of estrogen plus progestin reduces the risk of endometrial cancer among postmenopausal women. The study was reported at the European Cancer Congress 2013 in Amsterdam (Abstract LBA13) by Rowan Chlebowski, MD,...

breast cancer
issues in oncology

Breast Cancer Treatment in 10 Years: George Sledge, MD, Offers His Predictions

In a keynote lecture during the 2013 Breast Cancer Symposium breast cancer expert and ASCO Past President George Sledge, MD, offered five predictions for the future of the medical management of breast cancer. Dr. Sledge is now Chief of Oncology at Stanford University School of Medicine, Palo Alto,...

issues in oncology
breast cancer

Following Neoadjuvant Chemotherapy, Biomarkers Change in 41% of Breast Cancer Patients

After neoadjuvant chemotherapy, 41% of early breast cancer patients experienced a change in status for the estrogen receptor, progesterone receptor, or HER2 oncogene, researchers from The University of Texas MD Anderson Cancer Center reported at the 2013 Breast Cancer Symposium in San Francisco...

breast cancer
issues in oncology

Could MRI Be a Better Breast Cancer Screening Tool Than Mammography?

German investigators reported at the 2013 Breast Cancer Symposium in San Francisco that an abridged magnetic resonance imaging (MRI) protocol can accurately detect cancers among women whose mammographic screenings were negative (Abstract 1). MRI, therefore, may reveal the type of tumor that...

breast cancer

Study Reveals Best of Three Schedules of Nab-paclitaxel/Bevacizumab in Metastatic Breast Cancer

In a phase II study evaluating three dosing regimens of nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) given with bevacizumab (Avastin), weekly dosing of nab-paclitaxel resulted in the highest overall response rate and longest progression-free survival. The schedule of nab-paclitaxel given...

Advertisement

Advertisement



Advertisement